News | August 12, 2007

Removing Large Thrombus Prior to DES Implant Improves Outcomes

August 13, 2007 – A study published in the Journal of the American College of Cardiology showed that when AngioJet thrombectomy is used to remove large thrombus before placement of a drug-eluting stent (DES), it is associated with significantly lower rates of subsequent death, repeat heart attack and stent thrombosis.

The work is authored by Dr. George Sianos and colleagues at the ThoraxCenter in Rotterdam, the Netherlands, and appears in the Journal of the American College of cardiology (JACC), volume 50, number 7, dated August 14, 2007. The publication can be viewed on-line at http://content.onlinejacc.org.

Dr. Sianos analyzed 812 consecutive heart attack patients receiving a DES. Twenty-eight percent of the patients had large thrombus that complicated their treatment. These patients had a much higher incidence of serious adverse events out to two years after treatment, compared to the other patients who did not have large thrombus. The important exceptions were patients whose initial large thrombus was removed with AngioJet thrombectomy before stenting: these patients had a low incidence of serious adverse outcomes, similar to those patients with little or no thrombus to begin with. AngioJet thrombectomy was the single most powerful statistical predictor of a good clinical outcome in such patients.

Said Robert G. Dutcher, CEO of Possis Medical, Inc., "This important study demonstrates that unresolved large thrombus is common in acute coronary cases, and that placing a DES without first removing the thrombus contributes significantly to later life-threatening complications, including stent thrombosis. AngioJet thrombectomy lowers this risk by safely converting a clotted vessel that is at high risk for worse clinical outcomes into an un-clotted, low-risk vessel that can be successfully stented. We believe these results offer an important perspective that addresses some of the current uncertainty regarding DES use in higher-risk settings."

According to Dutcher, Dr. Sianos presented these key results at several important medical meetings in the last year, including the October 2006 Transcatheter Cardiovascular Therapeutics Conference in Washington D.C., and the November 2006 annual meeting of the American Heart Association in Chicago.

"Publication in the JACC, a very prestigious peer-reviewed journal, significantly increases the visibility of Dr. Sianos' results to the entire cardiology community. We believe this will have a favorable effect on the treatment choices made by the interventionalists who treat these seriously ill patients," concluded Dutcher.

For more information: http://content.onlinejacc.org

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init